LAVAL, Quebec, June 16, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), announced today that it will hold a conference call at 1:00 p.m. Eastern Time on Tuesday, June 21, 2022to discuss business progress and other Company developments, as well as financial results for the 2022 fiscal year ended March 31, 2022.
The conference call will be available by telephone by dialing toll-free at 844-836-8745 for WE callers or +1 412-317-5499 for international callers and using the entry code 316432. A webcast of the call can be viewed at https://app.webinar.net/RLkpwLG5mAx or on the Company’s Investor Relations section of the website: https://www.acastipharma.com/investors/.
A webcast will be available on the Company’s website. Investor news/Events section of the site (https://www.acastipharma.com/investors/) through June 21, 2023. A telephone replay of the call will be available approximately one hour after the call, by June 28, 2022and can be accessed by calling 877-344-7529 for WE callers or +1 412-317-0088 for international callers and entering the replay passcode: 1970306.
Acasti is a late-stage specialty pharmaceutical company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Acasti’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, increased efficacy, reduced side effects and more convenient drug delivery, all which could help increase treatment adherence and improve patient outcomes.
Acasti’s three lead clinical assets have each received orphan drug designation from the FDA, which grants the assets seven years of market exclusivity after the launch in United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti’s main clinical assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs at the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (AT), a progressive neurodegenerative genetic disease that primarily affects children, resulting in severe disability and for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting postherpetic neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage caused by the varicella zoster (shingles) virus, which can persist for periods of time. months or even years. For more information, please visit: https://www.acastipharma.com/en.
Statements contained in this press release that are not statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of the WE Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, “Forward-Looking Statements”). These forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Acasti’s actual results to differ materially from historical results or any future results expressed or implied by these forward-looking statements. . In addition to statements that explicitly describe such risks and uncertainties, readers are urged to review statements labeled with the terms “believes”, “believes”, “expects”, “intends”, “anticipates ‘, ‘estimates’, ‘potential’, ‘should’, ‘may’, ‘shall’, ‘plans’, ‘continues’, ‘targeted’ or other similar expressions such as being uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
These forward-looking statements are based on Acasti’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and timing of events could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions of the study phase 3 safety test planned for GTX-104 and Acasti’s other preclinical and clinical trials; (ii) regulatory requirements or developments and the outcome of meetings with the FDA; (iii) changes to clinical trial designs and regulatory pathways; (iv) legislative, regulatory, political and economic developments; (v) costs associated with Acasti’s clinical trials; and (vi) the effects of COVID-19 on clinical programs and business operations (i) the success and timing of regulatory submissions and preclinical and clinical trials; (ii) regulatory requirements or changes; (iii) changes to clinical trial designs and regulatory pathways; (iv) legislative, regulatory, political and economic developments, and (v) the effects of COVID-19 on clinical programs and business operations. The foregoing discussion of important factors that could cause actual events to differ from expectations should not be construed as complete and should be read in conjunction with the statements that are included herein and elsewhere, including the risk factors detailed in the documents that have been and can be filed. by Acasti from time to time with the SECOND. All forward-looking statements contained in this press release speak only as of the date on which they were made. Acasti undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.
Neither NASDAQ, TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Chief executive officer
Email: [email protected]
Lytham Partners, LLC
Email: [email protected]
Source: Acasti Pharma, Inc.
2022 GlobeNewswire, Inc., source Press releases – Canada